NY-ESO-1 is a Ubiquitous Immunotherapeutic Target Antigen for Patients with Myxoid/ Round Cell Liposarcoma

BACKGROUND: Myxoid/ round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for more than one third of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-E...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Pollack, Seth M., Jungbluth, Achim A., Hoch, Benjamin L., Farrar, Erik A., Bleakley, Marie, Schneider, David J., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, Ernest U., Jones, Robin L., Yee, Cassian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2012
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3361576/
https://ncbi.nlm.nih.gov/pubmed/22359263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27446
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items